Stoke Therapeutics, Inc. ( STOK ) Reports Q2 Loss, Tops Revenue Estimates
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of +29.82% and +181.98%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
- Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment period ...
Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome - Stoke Therapeutics ( NASDAQ:STOK ) , Biogen ( NASDAQ:BIIB )
- Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment period - - Dravet syndrome is a rare genetic disease characterized by refractory seizures and neurodevelopmental impairments, with no currently approved medicines that ...
Merus N.V. ( MRUS ) Reports Q2 Loss, Misses Revenue Estimates
Merus (MRUS) delivered earnings and revenue surprises of -90.60% and -15.41%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up
BIIB posts Q2 earnings and sales beat, lifts 2025 outlook on new drug growth and displays resilient MS performance.
Analysts Estimate Stoke Therapeutics, Inc. ( STOK ) to Report a Decline in Earnings: What to Look Out for
Stoke Therapeutics (STOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
This Verint Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Clearside Biomedical ( NASDAQ:CLSD ) , American Healthcare REIT ( NYSE:AHR )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Baird analyst Wesley Golladay initiated coverage on American Healthcare REIT, Inc.
Wall Street Analysts Think Stoke Therapeutics ( STOK ) Could Surge 132.4%: Read This Before Placing a Bet
The consensus price target hints at a 132.4% upside potential for Stoke Therapeutics (STOK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Stoke Therapeutics, Inc. ( STOK ) Tops Q1 Earnings and Revenue Estimates
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of 613.51% and 1,391.01%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Doximity Q4 Earnings Likely to Reflect Strong Product Momentum
Doximity's Q4 performance likely witnessed strong product-driven gains from new modules and integrated programs, though early revenue pull-forward might have tempered sequential growth.
BIIB's Q1 Earnings Miss, Revenues Top Mark, 2025 EPS Guidance Cut
Biogen reports mixed first-quarter 2025 results. It also lowers its EPS guidance for the current year.
CG Oncology, Inc. ( CGON ) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
CG Oncology, Inc. (CGON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stoke Therapeutics, Inc. ( STOK ) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Stoke Therapeutics (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Biogen Keep the Beat Streak Alive This Earnings Season?
In the first quarter, lower sales of BIIB's multiple sclerosis drugs are likely to have been offset by revenues from new drugs.
Stoke Therapeutics ( STOK ) Upgraded to Buy: What Does It Mean for the Stock?
Stoke Therapeutics (STOK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Stoke Therapeutics ( STOK ) Soars 12.0%: Is Further Upside Left in the Stock?
Stoke Therapeutics (STOK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Stoke Therapeutics, Inc. ( STOK ) Reports Q4 Loss, Tops Revenue Estimates
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of 64.71% and 483.59%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Stoke Therapeutics, Inc. ( STOK ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Stoke Therapeutics (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Argenx ( ARGX ) Surges 4.1%: Is This an Indication of Further Gains?
Argenx (ARGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
ChromaDex ( CDXC ) Q4 Earnings and Revenues Surpass Estimates
ChromaDex (CDXC) delivered earnings and revenue surprises of 50% and 7.47%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal - Stoke Therapeutics ( NASDAQ:STOK ) , Biogen ( NASDAQ:BIIB )
Biogen secures rights to commercialize zorevunersen outside North America, while Stoke leads global development and retains U.S. rights. Stoke receives $165 million upfront, up to $385 million in milestones, and royalties, with a Phase 3 trial set to begin in Q2 2025.
Strength Seen in Stoke Therapeutics ( STOK ) : Can Its 9.4% Jump Turn into More Strength?
Stoke Therapeutics (STOK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?
Here, we discuss some reasons why investing in STOK now may turn out to be a prudent move.
The Zacks Analyst Blog Highlights ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex
ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex are part of the Zacks top Analyst Blog.
4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow
Here, we discuss four biotech stocks, ADMA, TARS, STOK and CDXC, which have returned more than 50% year to date and have room for more growth in 2025.
STOK Shares Up on FDA's Breakthrough Tag for Dravet Syndrome Drug
The FDA bestows a Breakthrough Therapy designation to Stoke Therapeutics' zorevunersen for the treatment of Dravet syndrome. Stock rises.
Pure Storage Posts Upbeat Results, Joins Cross Country Healthcare, Marvell Technology, Stoke Therapeutics And Other Big Stocks Moving Higher On Wednesday - Altimmune ( NASDAQ:ALT ) , Bitdeer Technologies ( NASDAQ:BTDR )
U.S. stocks were higher, with the Dow Jones index gaining more than 150 points on Wednesday. Shares of Pure Storage Inc PSTG gained 26.1% to $67.48 after the company reported better-than-expected third-quarter financial results and issued fourth-quarter guidance above estimates.
Stoke Therapeutics ( STOK ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Stoke Therapeutics (STOK) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential ...
Wall Street Analysts Believe Stoke Therapeutics ( STOK ) Could Rally 66.84%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 66.8% in Stoke Therapeutics (STOK). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Stoke Therapeutics, Inc. ( STOK ) Reports Q3 Loss, Tops Revenue Estimates
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of 9.62% and 41.65%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Fortrea Holdings Inc. ( FTRE ) Reports Next Week: Wall Street Expects Earnings Growth
Fortrea Holdings Inc. (FTRE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stoke Therapeutics, Inc. ( STOK ) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Stoke Therapeutics (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stoke Therapeutics, Inc. ( STOK ) Reports Q2 Loss, Tops Revenue Estimates
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of 19.30% and 45.08%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Urogen Pharma ( URGN ) Expected to Beat Earnings Estimates: Should You Buy?
Urogen Pharma (URGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Enerpac Tool Group, Singular Genomics Systems And 3 Stocks To Watch On Monday - Enerpac Tool Group ( NYSE:EPAC )
With U.S. stock futures trading slightly higher this morning on Monday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Enerpac Tool Group Corp. EPAC to report quarterly earnings at 47 cents per share on revenue of $153.20 million after the closing bell.
Analyst Expectations For Stoke Therapeutics's Future
Stoke Therapeutics ( NASDAQ:STOK ) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding ...
Stoke Therapeutics, Inc. ( STOK ) Reports Q1 Loss, Tops Revenue Estimates
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of 5% and 26.61%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Axsome Therapeutics ( AXSM ) Q1 Earnings Expected to Decline
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Stoke Therapeutics, Inc. ( STOK ) Q1 Earnings Expected to Decline
Stoke Therapeutics (STOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stoke Therapeutics ( STOK ) Up on Upbeat Dravet Syndrome Study Data
Stoke Therapeutics (STOK) gains on meaningful clinical data from STK-001 studies for the treatment of Dravet syndrome.
What's Going On With Stoke Therapeutics Stock Tuesday? - Stoke Therapeutics ( NASDAQ:STOK )
Stoke Therapeutics Inc STOK shares are rising in Tuesday's after-hours session, riding a wave a momentum higher despite announcing a proposed public offering after the bell. What To Know: After the market close on Tuesday, Stoke Therapeutics announced a proposed underwritten public offering of up ...
Crude Oil Moves Lower; TD SYNNEX Earnings Top Estimates - Cardlytics ( NASDAQ:CDLX ) , AppTech Payments ( NASDAQ:APCX )
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining over 80 points on Tuesday. The Dow traded up 0.21% to 39,397.20 while the NASDAQ rose 0.23% to 16,421.62. The S&P 500 also rose, gaining, 0.17% to 5,227.03. Consumer discretionary shares jumped by 0.6% on Monday.
Dow Gains 100 Points; McCormick Posts Upbeat Results - Cardlytics ( NASDAQ:CDLX ) , AppTech Payments ( NASDAQ:APCX )
U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 100 points on Tuesday. The Dow traded up 0.25% to 39,413.30 while the NASDAQ rose 0.27% to 16,448.55. The S&P 500 also rose, gaining, 0.27% to 5,232.36. Consumer discretionary shares jumped by 0.8% on Monday.
Nasdaq Gains Over 50 Points; US Durable Goods Orders Rise In February - C3is ( NASDAQ:CISS ) , AppTech Payments ( NASDAQ:APCX )
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining over 50 points on Tuesday. The Dow traded up 0.08% to 39,346.40 while the NASDAQ rose 0.39% to 16,448.92. The S&P 500 also fell, dropping, 0.23% to 5,230.19. Consumer discretionary shares jumped by 0.7% on Monday.
Why Is Stoke Therapeutics Stock Trading Higher On Tuesday? - Stoke Therapeutics ( NASDAQ:STOK )
Monday, Stoke Therapeutics Inc STOK released new data from two open-label Phase 1/2a studies and two open-label extension ( OLE ) studies of children and adolescents ages 2 to 18 with Dravet syndrome who were treated with STK-001.
Tesla To $120? Here Are 10 Top Analyst Forecasts For Tuesday - Tesla ( NASDAQ:TSLA )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Keybanc boosted the price target for Worthington Steel, Inc. WS from $31 to $39.
Why Stoke Therapeutics Shares Are Trading Higher By Around 70%; Here Are 20 Stocks Moving Premarket - Stoke Therapeutics ( NASDAQ:STOK )
Shares of Stoke Therapeutics, Inc. STOK rose sharply in today's pre-market trading after the company announced Phase 1/2a data supporting the potential for STK-001 in Dravet syndrome. Stoke Therapeutics shares jumped 69.7% to $11.03 in pre-market trading Here are some other stocks moving in ...
Stoke Therapeutics, Inc. ( STOK ) Reports Q4 Loss, Lags Revenue Estimates
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of 3.23% and 24.34%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Stoke Therapeutics Stock Rockets On Phase 1/2a Data: Here's Why - Stoke Therapeutics ( NASDAQ:STOK )
Stoke Therapeutics, Inc. STOK reported its fourth-quarter financial results and announced Phase 1/2a end of study data after the bell on Monday. Here's a look at the highlights. The Details: The company reported quarterly losses of 60 cents per share which beat the analyst consensus estimate of ...
Why Earnings Season Could Be Great for Stoke Therapeutics ( STOK )
Stoke Therapeutics (STOK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
